艾司西酞普兰联合舒肝解郁胶囊治疗2型糖尿病伴发轻、中度抑郁的对照研究

Acontrol study of escitalopram and shugan-jieyu capsule for therapy type 2 diabetes patients combined withmildor or moderate depression

目的 探讨艾司西酞普兰联合舒肝解郁胶囊治疗2型糖尿病伴发轻、中度抑郁的疗效和安全性.方法 符ICD-10诊断标准的62例2型糖尿病伴发轻、中度抑郁患者随机分成两组各31例,对照组单用艾司西酞普兰治疗,10 ～ 20 mg/日；治疗组则在此基础上,联合舒肝解郁胶囊（0.72～1.44 g/日）治疗,疗程为8周.治疗前和治疗第1、2、4、6、8周末采用HAMD17、TESS对患者抑郁程度和副反应进行评定.结果 总有效率治疗组为93.5％,对照组为90.3％,两组比较.差异无统计学意义（P＞0.05）；治疗8周末,与对照组相比,治疗组HAMD评分的减分率相当,差异无统计学意义（P＞0.05）.两组TESS评分比较,差异有统计学意义（P＜0.01）.结论 艾司西酞普兰联合舒肝解郁胶囊治疗2型糖尿病伴发轻、中度抑郁安全有效,副反应少,依从性较好.

Objective To evaluate the clinical effectiveness and safety of escitalopram and shugan-jieyu capsule for therapy T2DM （type 2 diabetes mellitus） patientswith mild or moderate depression. Methods 62 T2DM patients with mild or moderate depression according to the depression standardofICD-10 were divided into test and control group ,31 patients in each group, patients in control group reveived escitalopram only, 10 -20mg/ d;patients in test group received eseitalopram and shugan-jieyu capsule（0.72 - 1.44g/d） ,last for 8weeks. Assess the depression and side reaction before treatment and at the end of 1,2,4,6,8weekend by using Hamilton Depression Scale（HAMD） and Treatment Emergent Symptom Scale（TESS）. Results Total effectiveness rate for test group was 93. 5% , and for control group was90. 3% , the differeces between the two groups present no statistically significant（P 〉 0. 05 ）. The differences of the HAMD assessment between the both groups presentno statistical significant （ P 〉 0. 05 ）. But TESS score decrease rate present statistically significant （ P 〈 0. 05 ） between the two groups atthe eighth weekend. Conclusions Escitaloptam and shugan-jieyu capsule can improve thedepression of the T2DM patients effectively, and with littleside-reaction.